Overview

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Status:
Terminated
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dynavax Technologies Corporation